Lv3
380 积分 2023-09-24 加入
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
5天前
已完结
Idarubicin versus Epirubicin in Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: An Open-label, Randomized, Phase IV Trial
10天前
已完结
Role of contrast enhanced ultrasound in radiofrequency ablation of metastatic liver carcinoma
22天前
已完结
Transcatheter embolization therapy in liver cancer: an update of clinical evidences
26天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
26天前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
28天前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
28天前
已完结
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
28天前
已完结
Local and Regional Therapies for Hepatocellular Carcinoma
1个月前
已完结
Editorial: HES V2.0: Advancing biomarker-based surveillance for HCC - Promise and remaining gaps
1个月前
已完结
皖公网安备34019202002308
